Swipe om te navigeren naar een ander artikel
Diabetic peripheral neuropathy (DPN) occurs in 26–47 % of diabetes patients and may have negative impacts on physical functioning, sleep, well-being, and quality of life. The Diabetic Peripheral Neuropathic Pain Impact measure (DPNPI) was developed to measure disease impacts and treatment effects. Presented are the DPNPI conceptual development and validation findings.
The DPNPI was developed following the FDA Guidance for Industry on patient-reported outcome (PRO) measures. Concept elicitation (CE) included literature review, clinical expert interviews, and patient interviews/focus groups. Qualitative data were analyzed following grounded theory principles, and draft items were cognitively debriefed. The measure underwent psychometric validation, and an a priori statistical analysis plan assessed the measurement model, reliability, and validity. Simultaneous analyses of item functioning were conducted using Rasch measurement theory (RMT). All tests were performed for the total score and each domain.
Twenty-five patients and three clinical experts participated in CE which resulted in a 27-item validation ready measure. In the validation study (N = 124), nine draft items were dropped due to high missing data and/or high correlations between items. Factor analysis revealed three domains: physical functioning/mobility, sleep, and daily activities. RMT confirmed adequate item fit and placement within domains. Internal consistency ranged from 0.91 to 0.96 and test–retest from 0.84 to 0.91. All prespecified hypotheses for convergent and discriminant validity were met.
CE and psychometric results provide evidence that the final, 18-item DPNPI is a reliable and valid PRO measure of disease impacts and treatment for DPNP. Further validation work should include responsiveness assessment.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Tesfaye, S., Vileikyte, L., Rayman, G., Sindrup, S., Perkins, B., Baconja, M., et al. (2011). Painful diabetic peripheral neuropathy: Consensus recommendations on diagnosis, assessment and management. Diabetes/Metabolism Research and Reviews,. doi: 10.1002/dmrr.1225.
Armstrong, D. G., Chappell, A. S., Le, T. K., Kajdasz, D. K., Backonja, M., D’Souza, D. N., et al. (2007). Duloxetine for the management of diabetic peripheral neuropathic pain: Evaluation of functional outcomes. Pain Medicine,8(5), 410–418. doi: 10.1111/j.1526-4637.2007.00276.x. CrossRefPubMed
Baron, R., Brunnmuller, U., Brasser, M., May, M., & Binder, A. (2008). Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study. European Journal of Pain,12(7), 850–858. doi: 10.1016/j.ejpain.2007.12.004. CrossRefPubMed
Currie, C. J., Poole, C. D., Woehl, A., Morgan, C. L., Cawley, S., Rousculp, M. D., et al. (2006). The health-related utility and health-related quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy. Diabetologia,49(10), 2272–2280. doi: 10.1007/s00125-006-0380-7. CrossRefPubMed
Van Acker, K., Bouhassira, D., De Bacquer, D., Weiss, S., Matthys, K., Raemen, H., et al. (2009). Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes & Metabolism,35(3), 206–213. doi: 10.1016/j.diabet.2008.11.004. CrossRef
Gore, M., Brandenburg, N. A., Dukes, E., Hoffman, D. L., Tai, K. S., & Stacey, B. (2005). Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. Journal of Pain and Symptom Management,30(4), 374–385. doi: 10.1016/j.jpainsymman.2005.04.009. CrossRefPubMed
Lewko, J., Politynska, B., Kochanowicz, J., Zarzycki, W., Okruszko, A., Sierakowska, M., et al. (2007). Quality of life and its relationship to the degree of illness acceptance in patients with diabetes and peripheral diabetic neuropathy. Advances in Medicine and Science,52(Suppl 1), 144–146.
Guidance for industry: patient-reported outcome measures, use in medical product development to support labeling claims. (2009). Rockville, MD: U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Center for Biologics Evaluation and Research : Center for Devices and Radiological Health.
Patrick, D. L., Burke, L. B., Gwaltney, C. J., Leidy, N. K., Martin, M. L., & Molsen, E., et al. (2011). Content validity—establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: Part 2—assessing respondent understanding. Value Health,14(8), 978–988. CrossRefPubMed
Patrick, D. L., Burke, L. B., Gwaltney, C. J., Leidy, N. K., Martin, M. L., & Molsen, E., et al. (2011). Content validity—establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: Part 1—eliciting concepts for a new PRO instrument. Value Health,14(8), 967–977. CrossRefPubMed
Atlas.ti. Qualitative Data Analysis. (2014). Retrieved from http://www.atlasti.com/index.html.
Corbin, J. M., & Strauss, A. L. (2008). Basics of qualitative research: Techniques and procedures. Los Angeles, CA: Sage.
Wild, D. J., Clayson, D. J., Keating, K., & Gondek, K. (2005). Validation of a patient-administered questionnaire to measure the activity impairment experienced by women with uncomplicated urinary tract infection: The Activity Impairment Assessment (AIA). Health Quality of Life Outcomes,3, 42. doi: 10.1186/1477-7525-3-42. PubMedCentralCrossRefPubMed
Sheehan, D. V. (1983). The Anxiety Disease. New York, NY: Charles Scribner and Sons.
Endicott, J., Nee, J., Harrison, W., & Blumenthal, R. (1993). Quality of life enjoyment and satisfaction questionnaire: A new measure. Psychopharmacology Bulletin,29(2), 321–326. PubMed
Ware, J. E, Jr. (2000). SF-36 health survey update. Spine (Phila Pa 1976),25(24), 3130–3139. CrossRef
Hays, R. D. (1992). Sleep measures. In A. L. Stewart & J. E. Ware (Eds.), Measuring functioning and well-being: The medical outcomes study approach (pp. 235–259). Durham, NC: Duke University Press.
RUMM2030, RUMM Laboratory Pty Ltd. (2014). Retrieved from http://www.rummlab.com.au/.
Lai, J.-S., & Eton, D. T. (2002). Clinically Meaningful Gaps. Rasch Measurement Transactions,15(4), 850.
Cappelleri, J. C., Zou, K. H., Bushmakin, A. G., Alvir, J. M. J., Alemayehu, D., & Symonds, T. (2014). Patient-reported outcomes: Measurement, implementation and interpretation. Boca Raton: CRC Press.
de Vet, H. C. W., Terwee, C. B., Mokkink, L. B., & Knol, D. L. (2011). Measurement in medicine. New York: Cambridge University Press. CrossRef
Fayers, P. M., & Machin, D. (2007). Quality of life: The assessment, analysis and interpretation of patient-reported outcomes. Chichester, England: Wiley. CrossRef
Fabrigar, L. R., Wegener, D. T., MacCallum, R. C., & Strahan, E. J. (1999). Evaluating the use of exploratory factor analysis in psychological research. Psychological Methods,4(3), 272–299. CrossRef
Floyd, F. J., & Widaman, K. F. (1995). Factor analysis in the development and refinement of clinical assessment instruments. Psychological Assessment,7(3), 286–299. CrossRef
Pett, M. A., Lackey, N. R., & Sullivan, J. J. (2003). Making sense of factor analysis: The use of factor analysis for instrument development in health care research. Thousand Oaks, CA: Sage Publications.
- Development and validation of the Diabetic Peripheral Neuropathic Pain Impact (DPNPI) measure, a patient-reported outcome measure
Steven I. Blum
Donald M. Bushnell
- Springer International Publishing